ÆÄÇʷΟÀÌÆÛ´Â ÀڱðæºÎ¾Ï ¿øÀÎ ¹ÙÀÌ·¯½ºÀÎ HPV À¯ÀüÇüÀÇ Áö¼ÓÀûÀÎ °¨¿°À» Á¤È®ÇÏ°Ô Áø´ÜÇÏ¿© ¾ÏÀÇ Á¶±âÁø´Ü, ¿¹¹æ ¹× È¿°úÀûÀÎ Áúȯ°ü¸®°¡ °¡´ÉÇÕ´Ï´Ù. 19Á¾ÀÇ °íÀ§Ç豺 HPVÀ¯ÀüÇü°ú 17Á¾ÀÇ ÀúÀ§Ç豺 HPV À¯ÀüÇüÀ» Æ÷ÇÔÇÑ 46Á¾ÀÇ HPVÀ¯ÀüÇüÀ» ±¤´ë¿ªÀ¸·Î ÆÇº°ÇÕ´Ï´Ù.
 

±âÁ¸ °Ë»ç¹ýº¸´Ù ¿ì¼öÇÑ Áø´Ü Á¤È®µµ
¾ÈÀü¼º¤ýÀ¯È¿¼º¿¡ ´ëÇÑ º¸°Çº¹ÁöºÎ ´Ù±â°ü Æò°¡¸¦ °ÅÃÄ ½ÅÀÇ·á±â¼ú ÀÎÁõ ȹµæ
º¸°Çº¹ÁöºÎ Á¦ 2011-115 °í½Ã ³»¿ë :
¢º ±âÁ¸ÀÇ DNA Chip °Ë»çº¸´Ù Áø´ÜÁ¤È®µµ ¿ì¼ö
¢º ¿°±â¼­¿­¹ý°ú ³ôÀº ÀÏÄ¡À²
¢º Áߺ¹°¨¿° °ËÃâ¿¡ À־´Â ¿°±â¼­¿­¹ý º¸´Ù ¿ì¼ö

³ôÀº ¹Î°¨µµ
ÃÖÀú °ËÃâÇѵµ (LOD) : 30~3000 copies/input
ÀÓ»ó ¹Î°¨µµ : 96.2% / ÀÓ»ó Æ¯À̵µ : 92.1% (K=0.969)

¼¼°è ÃÖ°í¼öÁØÀÇ ±¤´ë¿ª À¯ÀüÇü ÇØ»óµµ
°¡Àå ¸¹Àº ¼öÀÇ HPV À¯ÀüÇü ÆÇº°ÀÌ °¡´É
±âÁ¸ °Ë»ç¹ýÀÌ °ËÃâÇÏÁö ¸øÇÏ´Â HPV À¯ÀüÇü±îÁö ÆÇº°

Æí¸®¼º
´ë¿ë·® ÀÚµ¿È­ ºÐ¼® : 96 tests/run or 384 tests/run
ÇÁ·Î±×·¥À» ÅëÇÑ À翬¼º ÀÖ´Â °á°ú ȹµæ

°ËÃâ °¡´ÉÇÑ HPV À¯ÀüÇü

High risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68/73, 82
Probable high risk 26, 53, 66, 69
Low risk 6, 11, 34, 40, 42, 43, 44, 54, 55, 61, 62, 67, 70, 72, 81, 83, 89
Undetermined risk 27, 30, 64, 71, 74, 84, 86, 87, 102


benefits

À¯ÀüÀÚÀÇ °íÀ¯ÇÑ Áú·®À» ÃøÁ¤ÇϹǷΠºñƯÀÌÀûÀÎ ¹ÝÀÀÀ¸·Î ÀÎÇÑ ¿À·ù°¡ ¾ø¾î Á¤È®Çϰí À翬¼º ³ôÀº °á°ú¸¦ Á¦°øÇÏ´Â »õ·Î¿î °Ë»ç¹ýÀÔ´Ï´Ù.

ÇÁ·Îºê¸¦ ºÙÀÌ´Â DNAĨÀ̳ª Real-time PCR¹ý°ú °°Àº ´ëºÎºÐÀÇ °£Á¢ºÐ¼®¹ý°ú ´Þ¸®, ÆÄÇʷΟÀÌÆÛ´Â DNA³» À¯Àüº¯À̰¡ ¹ÐÁýÇÑ ÁÖ¿äºÎÀ§¸¦ Á÷Á¢ Àý´ÜÇØ ºÐ¼®ÇÏ´Â ½Å°³³äÀÇ RFMP¿ø¸®ÀÇ Áø´Ü¹ýÀ¸·Î¼­ °íµµÀÇ Á¤È®µµ¿Í ´ë¿ë·® ÀÚµ¿È­ ºÐ¼®´É·ÂÀ» Áö´Ï°í ÀÖ½À´Ï´Ù.

ÆÄÇʷΟÀÌÆÛ´Â ±â¼úÀÇ ¿ì¼ö¼ºÀ¸·Î Natureò¼ °ÔÀçµÇ¾úÀ¸¸ç ±¹³»»Ó¸¸ ¾Æ´Ï¶ó ¹Ì±¹, ÀϺ», Áß±¹¿¡ µî·ÏµÈ ƯÇ㸦 ±â¹ÝÀ¸·Î ƯÇã±â¼ú´ë»ó ¼¼Á¾´ë¿Õ»óÀ» ¼ö»óÇÏ´Â µî ±â¼úÀÇ ½Å·Ú¼ºÀ» ÀÔÁõ ¹Þ°í ÀÖ½À´Ï´Ù.


  1. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping. J Clin Virol. (2013)
  2. Analytical and Clinical Performances of a Restriction Fragment Mass Polymorphism Assay for Detection and Genotyping of a Wide Spectrum of Human Papillomaviruses. Journal of Medical Virology 83:471-482 (2011)
  3. High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry, Nature Protocols 3(9):1476-84 (2008)
  4. Human Papilloma Virus Genotyping Assay using Restriction Fragment Mass Polymorphism Analysis, and Its Comparison with Sequencing and Hybrid Capture Assays, Korean J Lab Med 27:62-8 (2007)
  5. Comparison of Efficacy of Human Papilloma Virus Genotyping Assays using Restriction Fragment Mass Polymorphism and DNA Chip Analysis in Patients with Abnormal Pap Smear and Uterine Cervical Cancer. The Korean Journal of Pathology 40:439-47 (2006)


Cat. No.

Product

Description

Content

GM3000

PapilloTyper

Genotyping of 74types of HPV

Test kit for 96 reactions

GM3010

PapilloTyper-PCR

HPV PCR Test

Test kit for 96 reactions

ÀÌ Á¦Ç°Àº "ÀÇ·á±â±â"À̸ç, "»ç¿ë»óÀÇ ÁÖÀÇ»çÇ×"°ú "»ç¿ë¹æ¹ý"À» Àß ÀÐ°í »ç¿ëÇϽʽÿÀ.
½ÄǰÀǾàǰ¾ÈÀüó À¯ÀüÀÚÁõÆøÀåÄ¡¿ë½Ã¾à Á¦Çã 13-71È£, Á¦Çã 13-410È£